Tonix Pharmaceuticals Holding Corp. (TNXP) Wednesday announced the in-licensing of worldwide rights to TNX-4800, a long-acting human monoclonal antibody that targets the Lyme disease-causing Borrelia bacteria.
TNX-4800 was developed by researchers at UMass Chan Medical School, which is licensing the technology to Tonix.
TNX-4800 is being developed for annual seasonal use, as one dose administered in the Spring to protect against Lyme disease through Fall, or the entire tick season in the U.S.
The company is planning an adaptive Phase 2/3 study of TNX-4800.
There are currently no FDA-approved vaccines or prophylactics to protect against Lyme Disease.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.